Brokerages positive on Australia's ALS after upbeat half-year results

ALS

18/11/2025 22:43

** Citi upgrades target price on ALS Ltd ALQ.AX to A$23.8 from A$19.45, maintains "buy" tag

** Laboratory testing services provider on Tuesday reported a 17.2% jump in underlying NPAT to A$178.4 million for HY

** Citi says co's commodities segment surprised on the upside with sample volumes up "low double-digit" compared to last year

** Says co's revised forecast of 12% to 14% organic revenue growth for commodities division appears conservative; brokerage estimates 15% growth

** Macquarie hikes EPS estimates for ALS by 6% to 7% for fiscals 2027, 2028 and 2029 each

** Says stock has had a "strong run and multiple", but should be supported by co's strong earnings growth profile which is above market and global peers

** Brokerage retains "outperform" rating, target price A$22.85

** Stock up 38.4% YTD, as of last close

 (Reporting by Nikita Maria Jino in Bengaluru)

 ((Nikita.Jino@thomsonreuters.com;))